Aptevo Therapeutics, Inc. APVO 深 滬
已收盤 05-08 16:00:00 美东时间
4.97
+0.110
+2.26%
華盛通- 最 高5.075
- 今 開4.885
- 成交量 3.27万股
- 最 低 4.835
- 昨 收 4.86
- 總市值 587.32万
- 52周最高 258.012
- 市盈率 靜 --
- 換手率 2.77%
- 52周最低 3.80
- 委 比 -39.22%
- 總股本 118.17万
- 歷史最高 68020444.80
- 量 比 0.30
- 振 幅 4.94%
- 歷史最低 3.80
- 每 手 1
- 風險率 30.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aptevo Therapeutic Announces 87% Clinical Benefit Rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection
The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in combination with venetoclax and azacitidine.
05-06 20:10
Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the analyst consensus estimate of $(8.10) by 23.09 percent. This is a 97.38 percent increase over losses of $(237.60) per share
03-26 20:55
Aptevo Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine In Newly Diagnosed AML Patients; Trials Deliver 86% Clinical Benefit Rate With Zero Patients Experiencing Common Symptom Of CRS
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidineSEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc.
03-10 20:16
10 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Icecure Medical (NASDAQ:ICCM) shares moved upwards by 17.7% to $0.68 d...
03-02 20:05
Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today
02-03 21:14
APVO stock has given up its prior gain. Aptevo Therapeutics shares were trading higher after the company entered into a $60 million equity line of credit agreement with Yorkville Advisors Global.
APVO stock has given up its prior gain. Aptevo Therapeutics shares were trading...
01-09 23:02
Aptevo Therapeutics shares are trading higher after the company entered into a $60 million equity line of credit agreement with Yorkville Advisors Global.
Aptevo Therapeutics shares are trading higher after the company entered into a ...
01-09 21:07
Aptevo Therapeutics Implements 1-for-18 Reverse Stock Split
Aptevo Therapeutics ( ($APVO) ) has shared an update. On July 24, 2025, Aptevo ...
2025-12-30 06:29
What's Going On With Aptevo Therapeutics Stock Today?
Shares of Aptevo Therapeutics are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.
2025-12-26 23:24
Aptevo Therapeutics shares are trading lower after the company announced a 1-for-18 reverse stock split.
Aptevo Therapeutics shares are trading lower after the company announced a 1-fo...
2025-12-26 21:07
